US.MRNA · Moderna

{
  "risk": {
    "level": "High",
    "reason": "risk management score < 5/10",
    "position": {
      "score": 0.9,
      "details": {
        "atrPct": 5.410616563298067,
        "turnoverUsdM": 425.331934,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 48.8878,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 10.8,
      "take_profit_price": 60.8313,
      "target_multiplier": 1.9,
      "technical_strength": 1.6,
      "take_profit_percent": 11
    },
    "positionPoints": 0.9,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 10.821233126596134,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 51.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 40.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 63.7438,
    "ma50": 58.4052,
    "close": 54.82,
    "prevClose": 57.92,
    "avgVolume20": 6172610,
    "volumeRatio": 1.26,
    "changePercent": -5.35
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.013870908082115774,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 1.1956585391412624,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 1.4793396500437621,
      "volat_points": 2,
      "day_range_pct": 0.08719445457862096,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 51.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 4.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 49,
        "contribution": 4.9
      },
      {
        "raw": 13.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 46.33,
        "contribution": 13.9
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 40.4,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 4.9/10分",
      "技術信號分析總分: 13.9/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.7,
      "資金流": 8.4,
      "市場環境": 6.6,
      "情緒分析": 2,
      "技術信號": 13.9,
      "風險管理": 4.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 425.331934,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.09
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 701.0184969000002,
                "ma50": 715.0880007999999,
                "name": "QQQ",
                "close": 687.98999,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.6945061500002,
                "ma50": 744.99000356,
                "name": "SPY",
                "close": 747.030029,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 5.410616563298067,
          "atrPoints": 1,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 2,
              "positiveHits": 2,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141090085,
                "url": "https://finnhub.io/api/news?id=cb92c7695a573ae9a1aa735a7a6b602d023a0f40809fbd6cc67e8b95a4057c73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...",
                "category": "company",
                "datetime": 1785625773,
                "headline": "Moderna (MRNA) Faces Norovirus Setback As MFLUSIVA FDA Decision Nears"
              },
              {
                "id": 141081727,
                "url": "https://finnhub.io/api/news?id=0e6b217ea0b704ea595a10ac7e41a3d97c4c6866d4197a0c10d8a2c6a799ae5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.",
                "category": "company",
                "datetime": 1785524454,
                "headline": "Moderna Inc (MRNA) (Q2 2026) Earnings Call Highlights: Revenue Beat and Pipeline Progress Amid ..."
              },
              {
                "id": 141081549,
                "url": "https://finnhub.io/api/news?id=8e5807917ad3962f527a25faccd33954fa586c6c2a18376f52be2d06d6f439e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.",
                "category": "company",
                "datetime": 1785521040,
                "headline": "MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback"
              },
              {
                "id": 141078119,
                "url": "https://finnhub.io/api/news?id=6d37bef2f33c33b4f6b6bfdf56597d464c5ea9a0b5ac0b25c4bcdeebf542418b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499801,
                "headline": "Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates"
              },
              {
                "id": 141079288,
                "url": "https://finnhub.io/api/news?id=fd73d347dd147f3649ce5c5b73510e7caedfd46a2f910fb34cf75b4a3016c588",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call July 31, 2026 8:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor RelationsStéphane...",
                "category": "company",
                "datetime": 1785499402,
                "headline": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141077361,
                "url": "https://finnhub.io/api/news?id=a0f0c5f8e5d5760b0b477b139ba5c2d18c0c6adf092582f7ad9a7b5a721d8a67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785496443,
                "headline": "Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026"
              },
              {
                "id": 141067188,
                "url": "https://finnhub.io/api/news?id=cc026c98fea4324709a01e8a4a3c5c612c09d3cd2a3302964a661cc3b6940004",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.",
                "category": "company",
                "datetime": 1785421262,
                "headline": "Moderna (MRNA) Q2 Earnings: What To Expect"
              },
              {
                "id": 141056001,
                "url": "https://finnhub.io/api/news?id=42d1ace2654ba2bd9f203d862d7fec3bb81edcd8e97e9999a70c3c7f1e26b553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain right now. Over five years, Moderna shareholders have seen the stock decline 85.6%, which puts the recent rebound in a much longer and still challenging context. Progress on the mRNA cancer program, including the recent Phase 1 trial start for mRNA-4200, can support sentiment on Moderna’s growth potential. At the...",
                "category": "company",
                "datetime": 1785341341,
                "headline": "Moderna (MRNA) Stock May Be Overvalued After Cancer Trial Start"
              }
            ],
            "raw_source": [
              {
                "id": 141090085,
                "url": "https://finnhub.io/api/news?id=cb92c7695a573ae9a1aa735a7a6b602d023a0f40809fbd6cc67e8b95a4057c73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...",
                "category": "company",
                "datetime": 1785625773,
                "headline": "Moderna (MRNA) Faces Norovirus Setback As MFLUSIVA FDA Decision Nears"
              },
              {
                "id": 141081727,
                "url": "https://finnhub.io/api/news?id=0e6b217ea0b704ea595a10ac7e41a3d97c4c6866d4197a0c10d8a2c6a799ae5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.",
                "category": "company",
                "datetime": 1785524454,
                "headline": "Moderna Inc (MRNA) (Q2 2026) Earnings Call Highlights: Revenue Beat and Pipeline Progress Amid ..."
              },
              {
                "id": 141081549,
                "url": "https://finnhub.io/api/news?id=8e5807917ad3962f527a25faccd33954fa586c6c2a18376f52be2d06d6f439e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.",
                "category": "company",
                "datetime": 1785521040,
                "headline": "MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback"
              },
              {
                "id": 141082486,
                "url": "https://finnhub.io/api/news?id=21fe1895d9ac65bb599d35683c6e6f056e64d3d7c4837373bce0b5341710b638",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204956103/image_2204956103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "BioNTech trades near cash value; the oncology pipeline looks undervalued. Click here to read more about BNTX.",
                "category": "company",
                "datetime": 1785520130,
                "headline": "BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free"
              },
              {
                "id": 141079232,
                "url": "https://finnhub.io/api/news?id=159623b026e0607fa80577aa52ddf408b57d1f135c78429e79947233fe70e49b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower",
                "category": "company",
                "datetime": 1785508239,
                "headline": "Moderna Q2 earnings beat estimates as norovirus vaccine stumbles"
              },
              {
                "id": 141079011,
                "url": "https://finnhub.io/api/news?id=97d9e222b054c1476b225754963b5acf752f93c797fd5c1c65e3d242e6a2ec01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss in its latest quarter, but shares traded slightly lower as the company’s earnings report highlighted the drugmaker’s ongoing struggle to break away from its pandemic-driven business model.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785506820,
                "headline": "Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?"
              },
              {
                "id": 141079234,
                "url": "https://finnhub.io/api/news?id=c40ab8e955d13abb37b786cfe5287080bfadd5793abe8221034d396f5ee3dca9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha",
                "category": "company",
                "datetime": 1785506644,
                "headline": "Moderna Q2 Earnings Call Highlights"
              },
              {
                "id": 141077642,
                "url": "https://finnhub.io/api/news?id=3223cbf246df2f33c69539037f774a50260cd33d10286f045a518ad8062cad57",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1785501301,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141078119,
                "url": "https://finnhub.io/api/news?id=6d37bef2f33c33b4f6b6bfdf56597d464c5ea9a0b5ac0b25c4bcdeebf542418b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499801,
                "headline": "Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates"
              },
              {
                "id": 141079288,
                "url": "https://finnhub.io/api/news?id=fd73d347dd147f3649ce5c5b73510e7caedfd46a2f910fb34cf75b4a3016c588",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call July 31, 2026 8:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor RelationsStéphane...",
                "category": "company",
                "datetime": 1785499402,
                "headline": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141077109,
                "url": "https://finnhub.io/api/news?id=f16d5a2dc9b6a4824034e9a6c0d771a4a457d491209a6f45740cd61bdbd2cfc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)",
                "category": "company",
                "datetime": 1785498389,
                "headline": "Stocks Rise Pre-Bell as Amazon Results Lift AI Trade Sentiment"
              },
              {
                "id": 141077360,
                "url": "https://finnhub.io/api/news?id=feadc898c39604ac58b85c95f9d3176aeea761452bbb6bc4f69f6cae69fdbaa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785497160,
                "headline": "Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?"
              },
              {
                "id": 141087997,
                "url": "https://finnhub.io/api/news?id=4caacbfb9100f8c9139b37721bfee97ef3989fd0afb2ded093e82f4cfa495084",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (MRNA) Q2 Earnings: Beat estimates with $145M in sales and a $1.97 EPS loss. Reaffirms 2026 sales guidance.",
                "category": "company",
                "datetime": 1785496990,
                "headline": "Moderna Burns Cash, Suffers Fresh Vaccine Setback"
              },
              {
                "id": 141077361,
                "url": "https://finnhub.io/api/news?id=a0f0c5f8e5d5760b0b477b139ba5c2d18c0c6adf092582f7ad9a7b5a721d8a67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785496443,
                "headline": "Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026"
              },
              {
                "id": 141077362,
                "url": "https://finnhub.io/api/news?id=dc1dfb1ce678963e373dc8acf68f295f9fe51a03af150eb0eac84b7190ec20b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous ...",
                "category": "company",
                "datetime": 1785495600,
                "headline": "Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141078331,
                "url": "https://finnhub.io/api/news?id=ac530d31eb48c583c6b8bbc1b91343789c5a8e500ff7be600e75e89b17e3ab3b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186886491/image_2186886491.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.",
                "category": "company",
                "datetime": 1785493846,
                "headline": "Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now"
              },
              {
                "id": 141079909,
                "url": "https://finnhub.io/api/news?id=a5a7705f07d9b232c16355122cc3473a9188034e2f288c75be991d6c3a809f66",
                "image": "https://image.cnbcfm.com/api/v1/image/108313757-1780058150187-gettyimages-2275740460-TFSPI_14052026-5453.jpeg?v=1780058175&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1785483901,
                "headline": "Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more"
              },
              {
                "id": 141078474,
                "url": "https://finnhub.io/api/news?id=4924c4d4a3733c4c77af4a5b8d10596bddf5c95e5af21a48d5f630a464a94aef",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) affirms FY2026 sales outlook from $2.138 billion to $2.138 billion vs $2.089 billion estimate.",
                "category": "company",
                "datetime": 1785481264,
                "headline": "Moderna Affirms FY2026 Sales Guidance of $2.138B vs $2.089B Est"
              },
              {
                "id": 141068643,
                "url": "https://finnhub.io/api/news?id=6f0b72b80f20cb1734cc4c653ea213e50f7ebf7604dda827380b5c51cba56cfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "There are fresh signs that fusion power startup Commonwealth Fusion Systems will list in the next two to three years.",
                "category": "company",
                "datetime": 1785426336,
                "headline": "When will fusion power startup Commonwealth Fusion Systems go public?"
              },
              {
                "id": 141067188,
                "url": "https://finnhub.io/api/news?id=cc026c98fea4324709a01e8a4a3c5c612c09d3cd2a3302964a661cc3b6940004",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.",
                "category": "company",
                "datetime": 1785421262,
                "headline": "Moderna (MRNA) Q2 Earnings: What To Expect"
              },
              {
                "id": 141057077,
                "url": "https://finnhub.io/api/news?id=4a73e97bf16c01c4763ccc1ac48e9fce315900a166893fe20d536f40103001c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.",
                "category": "company",
                "datetime": 1785344580,
                "headline": "Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?"
              },
              {
                "id": 141056001,
                "url": "https://finnhub.io/api/news?id=42d1ace2654ba2bd9f203d862d7fec3bb81edcd8e97e9999a70c3c7f1e26b553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain right now. Over five years, Moderna shareholders have seen the stock decline 85.6%, which puts the recent rebound in a much longer and still challenging context. Progress on the mRNA cancer program, including the recent Phase 1 trial start for mRNA-4200, can support sentiment on Moderna’s growth potential. At the...",
                "category": "company",
                "datetime": 1785341341,
                "headline": "Moderna (MRNA) Stock May Be Overvalued After Cancer Trial Start"
              },
              {
                "id": 141054570,
                "url": "https://finnhub.io/api/news?id=7a062cb0f57e72f12ca133cba9778cd83bcd77192d4de1dd4142cf922f41d010",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath […]",
                "category": "company",
                "datetime": 1785337503,
                "headline": "Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced"
              },
              {
                "id": 141053279,
                "url": "https://finnhub.io/api/news?id=a0f0df1b96fb612ea00f606fa308ad08c08fff23339b1ab08cadc9cee3998d9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In recent months, Moderna reported a very large year-on-year Q1 revenue increase that surpassed analyst expectations, secured two European approvals including the world’s first flu plus COVID combination vaccine mCOMBRIAX, and began a pivotal Phase 3 trial for its lung cancer candidate intismeran. This combination of new product approvals and late-stage oncology pipeline progress highlights Moderna’s effort to broaden its business well beyond its COVID-19 franchise. We’ll now examine how the...",
                "category": "company",
                "datetime": 1785330585,
                "headline": "Why Moderna (MRNA) Is Down 6.5% After Europe Clears Its First Flu-COVID Combo Vaccine"
              },
              {
                "id": 141052277,
                "url": "https://finnhub.io/api/news?id=2625622a16fd23e22e1bea637d0a6ab5014872dcc8587d4bdb5968cc04ba868c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.",
                "category": "company",
                "datetime": 1785326417,
                "headline": "3 Biotech Stocks With Massive Upside to Buy Before August Starts"
              },
              {
                "id": 141049147,
                "url": "https://finnhub.io/api/news?id=847f022feb42bf4d47a784124e1326cc42350ccd7a0f939c17b8e3547748713d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%.",
                "category": "company",
                "datetime": 1785285902,
                "headline": "1 Healthcare Stock to Keep an Eye On and 2 We Avoid"
              },
              {
                "id": 141045629,
                "url": "https://finnhub.io/api/news?id=9896d38833b64101df2a2a0f1f49cf45257fda96b8dd51902d04c599480ea14a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.",
                "category": "company",
                "datetime": 1785255709,
                "headline": "2 Major Reasons to Buy Moderna Stock Before July 31"
              },
              {
                "id": 141039020,
                "url": "https://finnhub.io/api/news?id=8fd1782ce05250991501094467121195fe3381f0424a31fb4a32d1bbfbab84c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).",
                "category": "company",
                "datetime": 1785200942,
                "headline": "Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 141038245,
                "url": "https://finnhub.io/api/news?id=47f74155c62b90bd68e5ca30079eeafceadd9ffd98e1024e5dcf70f7e7908c58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.",
                "category": "company",
                "datetime": 1785189004,
                "headline": "Moderna (MRNA) Laps the Stock Market: Here's Why"
              },
              {
                "id": 141037355,
                "url": "https://finnhub.io/api/news?id=39fec9f047840672f1016880d7063a68767b5c8011a8796005ee76165a2717a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.",
                "category": "company",
                "datetime": 1785183747,
                "headline": "After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?"
              },
              {
                "id": 141036351,
                "url": "https://finnhub.io/api/news?id=5b184e2138a7cf1b916297cca94bbf2d1b1ca16fe8b25b8f27bd6fce1dd88ee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.",
                "category": "company",
                "datetime": 1785177902,
                "headline": "Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)"
              },
              {
                "id": 141015956,
                "url": "https://finnhub.io/api/news?id=30c853daab5af443ab8a0c8862a8b56eabb48569926bf56471b440d71080bbab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/attachment/image/1d2aed9fc253168620c030b0153c6b23.png?io=w640",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.",
                "category": "company",
                "datetime": 1784970358,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141015118,
                "url": "https://finnhub.io/api/news?id=cbf5dc445b0c76d160194163974c25631e03fe21e4e10a18d4aafdb19b3e4b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.",
                "category": "company",
                "datetime": 1784939440,
                "headline": "FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions"
              },
              {
                "id": 141006520,
                "url": "https://finnhub.io/api/news?id=3aefd1a3b5bd534f69d2fcade197da65aeb3b00065b71bc03914a4c1346e14aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784901614,
                "headline": "Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know"
              },
              {
                "id": 140995023,
                "url": "https://finnhub.io/api/news?id=925ed259cfd744a1d6a25d64224d1e30210b5a3fba92b33ce75ac67e37fd04df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.",
                "category": "company",
                "datetime": 1784818907,
                "headline": "Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ..."
              },
              {
                "id": 140994788,
                "url": "https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.",
                "category": "company",
                "datetime": 1784818856,
                "headline": "Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"
              },
              {
                "id": 140998135,
                "url": "https://finnhub.io/api/news?id=97ee12753c510423248db8b35f41ebfbcd51905e784a842f30e78fe3eeee4d92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.",
                "category": "company",
                "datetime": 1784807075,
                "headline": "Earnings Preview: What To Expect From Moderna’s Report"
              },
              {
                "id": 140983367,
                "url": "https://finnhub.io/api/news?id=121dee6eb5b95230890bc77a0fb432c067d167b2adb9237f093d012c795d3f33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Cheiron Founders Cheiron co-founders (from left): Harshit Gupta, co-founder and chief technology officer; Minseok Bae, co-founder and CEO; and Jason Park, co-founder and chief product officer. LOS ALTOS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cheiron, the operating system for drug programs, today announced an $8 million seed round led by Menlo Ventures, with the backing and strategic support of industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pf",
                "category": "company",
                "datetime": 1784736000,
                "headline": "Cheiron Raises $8M Seed Led by Menlo Ventures to Build the Operating System for Drug Programs"
              },
              {
                "id": 140980977,
                "url": "https://finnhub.io/api/news?id=7a6528725d9c46a032b9aec4860fb2d1d0620a931ee06da19f7676b4d8235c80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in \"Hallucinating Value: Healthcare's AI Narrative.\"",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown"
              },
              {
                "id": 140979307,
                "url": "https://finnhub.io/api/news?id=ab1d76e1b33557d5f6d4d8c656c9abaf685f1cb4f7b217f4e4756b6285cf66c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...",
                "category": "company",
                "datetime": 1784694596,
                "headline": "Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?"
              },
              {
                "id": 140978883,
                "url": "https://finnhub.io/api/news?id=d78c0114452c0261f94eb1ca62c5f3010494eee1e76749bee9dc0779be07cab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee. The company has adjusted certain Board committee memberships alongside his appointment. The changes bring additional financial and life sciences experience into Moderna’s governance structure. Moderna, traded on NasdaqGS:MRNA, is drawing attention for a fresh governance update rather than product news. The stock closed at $59.66, with returns up 93.3% year to date and up 82.3% over the past year, set...",
                "category": "company",
                "datetime": 1784690424,
                "headline": "Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift"
              },
              {
                "id": 140978393,
                "url": "https://finnhub.io/api/news?id=143dd199ffc3732f0edb7b90bcea9a1e351dd89c2f0cb9ff5d841117d8cf8ee1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech has been on a tear lately.",
                "category": "company",
                "datetime": 1784679600,
                "headline": "Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?"
              },
              {
                "id": 140971289,
                "url": "https://finnhub.io/api/news?id=9a2a8d5b3f1dc00f623f077a22173abc8310497221db1355efc77c8c69b89b10",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $49 to $67.",
                "category": "company",
                "datetime": 1784623280,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $67"
              },
              {
                "id": 140966165,
                "url": "https://finnhub.io/api/news?id=34658b765cdec9863d3712d07ca568307568935179720cee2fd26da1dc4f64b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A fresh era of earnings growth may be on the horizon.",
                "category": "company",
                "datetime": 1784586600,
                "headline": "Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?"
              },
              {
                "id": 140966337,
                "url": "https://finnhub.io/api/news?id=dba9895e956dbc5290626a3989cd198396272214c3838d279d6740cf6005a48f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784584203,
                "headline": "Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 140934665,
                "url": "https://finnhub.io/api/news?id=156d625b8c8ea3b5425a1edc5e9873aeed003751d527274d43714d475eccc7dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784307466,
                "headline": "Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140934500,
                "url": "https://finnhub.io/api/news?id=b8d38ebc14f6fb86a9aaa49ca942ab31591c522f24a09a7b19d48899869a54d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.",
                "category": "company",
                "datetime": 1784300340,
                "headline": "MRNA Advances Cancer Pipeline With New Immunotherapy Study"
              },
              {
                "id": 140931633,
                "url": "https://finnhub.io/api/news?id=a3bb467eca89014e58136c2e5ec2ca3928bc78c3fbb500a9965da2dcc2a2a54d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to",
                "category": "company",
                "datetime": 1784288659,
                "headline": "Neglected Quant Safety Trade Makes a Comeback as AI Risks Rise"
              },
              {
                "id": 140933093,
                "url": "https://finnhub.io/api/news?id=a4cd3c507c482d8f1957c9ad2e3b0bb58a656a4187d89ec4a698b1241eeb7f45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.",
                "category": "company",
                "datetime": 1784282845,
                "headline": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances"
              },
              {
                "id": 140924528,
                "url": "https://finnhub.io/api/news?id=f1e1715ec5ef89b9077a66a3ae648149c25e397177105374f1afe0fa2ef540fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.",
                "category": "company",
                "datetime": 1784227263,
                "headline": "ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?"
              },
              {
                "id": 140921837,
                "url": "https://finnhub.io/api/news?id=192e750e79a3e75ab0d468b53d4de78fd222cc21fdcb5c63cb9253fb73f4301d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.",
                "category": "company",
                "datetime": 1784219700,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 140918921,
                "url": "https://finnhub.io/api/news?id=a55e4c8b6ce0a21c79c97c228a610dad6931a94cff4a46dfd5fe6ccc4b01ebfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents Anticipates receipt of a dividend from Genevant in Q3 2026 Expects to return up to approximate",
                "category": "company",
                "datetime": 1784201400,
                "headline": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders"
              },
              {
                "id": 140919029,
                "url": "https://finnhub.io/api/news?id=ec7dfff01ad9a972b4e1106cb3ba1b7e1a0767fd8854874d2a6bcf4e0c1e0d8b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced ...",
                "category": "company",
                "datetime": 1784199600,
                "headline": "Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors"
              },
              {
                "id": 140921643,
                "url": "https://finnhub.io/api/news?id=ad1db4b6be88d8cd0e3ddb4d5813892f40565c9119be0162b0369232b28fd01e",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic",
                "category": "company",
                "datetime": 1784185418,
                "headline": "Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors"
              },
              {
                "id": 140900040,
                "url": "https://finnhub.io/api/news?id=76e7485fea8bbc7883846148f4118bada996ba5602ddc83871a64492383b4f0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company’s late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a...",
                "category": "company",
                "datetime": 1784050500,
                "headline": "Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies"
              },
              {
                "id": 140893920,
                "url": "https://finnhub.io/api/news?id=47d6d4e74ed1db540632834dce38790a050e1f5ba2d4668c97c2e1fc020011b7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256895141/image_2256895141.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Markets remained mixed last week, with sector leadership continuing to rotate beneath a relatively stable broader market.",
                "category": "company",
                "datetime": 1783989300,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 140892671,
                "url": "https://finnhub.io/api/news?id=f5eb20fba93f312e07c310ee8bf8c0e66eadb4e3e9883c34d31c9724d1fcd058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.",
                "category": "company",
                "datetime": 1783979406,
                "headline": "Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140885957,
                "url": "https://finnhub.io/api/news?id=c3654f647a3a47105890017a1058d688704c7d5e8383e61c6ed4d24e55ec464f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.",
                "category": "company",
                "datetime": 1783948328,
                "headline": "What It Means To Hold Moderna Stock In A Crash"
              },
              {
                "id": 140886045,
                "url": "https://finnhub.io/api/news?id=cbed7f50e76169885f3ee752a5d4dc459a65e615e71f72c26bb80ca6f09f9856",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.",
                "category": "company",
                "datetime": 1783930800,
                "headline": "Moderna, Takeda and Capricor on the verge of notching big drug approvals"
              },
              {
                "id": 140884386,
                "url": "https://finnhub.io/api/news?id=af5eb902aca1992ec5be596a883f3a2dc814c0cdaac87d634e05625c0cd64bc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Monday, Jul, 13 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in...",
                "category": "company",
                "datetime": 1783930232,
                "headline": "US Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom"
              },
              {
                "id": 140866318,
                "url": "https://finnhub.io/api/news?id=de5a1bf97e4c73b4b8c964715ac59f0c6f06e02de4899d9fa077f93762668cfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stock Market Today: The Dow Jones index rises Friday while SK Hynix spikes in its U.S. debut. Chili's stock breaks out.",
                "category": "company",
                "datetime": 1783716242,
                "headline": "Stock Market Today: Dow Ends Higher; SK Hynix Jumps In U.S. Trading Debut; Moderna Tumbles"
              },
              {
                "id": 140866170,
                "url": "https://finnhub.io/api/news?id=a3aa35610973c4e09e72a60550a3a4d1ed78491ac6d94840e7900b3c81fd6d98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Updates with index/price moves and company/geopolitical news from the first paragraph.) US equit",
                "category": "company",
                "datetime": 1783716056,
                "headline": "Update: US Equity Indexes Rise as Diplomatic Engagements Between Washington, Iran Send Crude Oil Lower"
              },
              {
                "id": 140866172,
                "url": "https://finnhub.io/api/news?id=ad3d65785a11d0ff5301054e3e738273149c937f92547a09f1891e72fe313cdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Updates with market moves at the end of the day and weekly index changes.) US equities rose Frid",
                "category": "company",
                "datetime": 1783715129,
                "headline": "Update: US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talks"
              },
              {
                "id": 140865423,
                "url": "https://finnhub.io/api/news?id=9c8e4ce026832df4e7d0259af159f409a25c41849bb6baff96cdce34fe84e17b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May.",
                "category": "company",
                "datetime": 1783712233,
                "headline": "MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead?"
              },
              {
                "id": 140865010,
                "url": "https://finnhub.io/api/news?id=4c3d354a7751b7e3c25635309edaa7acf06881ecc4f247a89a15c996d87b178e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1783710301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140864232,
                "url": "https://finnhub.io/api/news?id=91a02918a5278124662a610b3899e8198d2c7971f595e01efcfbf99480df0d7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.",
                "category": "company",
                "datetime": 1783699478,
                "headline": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout"
              },
              {
                "id": 140863212,
                "url": "https://finnhub.io/api/news?id=37a712ddbbcb97c1e777b6e97d5101753ca739fd59fb9c22b266a1e2d9fdd0a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Iran war and a tug-of-war between AI stocks and other parts of the market have left the S&P 500 stuck in a range.  On Friday, the S&P 500’s healthcare sector was the only major sector trading down more than 0.1%: It was down 0.7%.  Moderna was the S&P’s biggest laggard, while UnitedHealth was the big drag on the Dow.",
                "category": "company",
                "datetime": 1783698237,
                "headline": "Only 1 Major S&P 500 Sector Is Really Struggling Today"
              },
              {
                "id": 140862289,
                "url": "https://finnhub.io/api/news?id=c8728c954ec0457bbc0355faa6edee84f50fc80691ec4a97c3b60539cf9855e5",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1783694100,
                "headline": "Which S&P500 stocks are gapping on Friday?"
              },
              {
                "id": 140860978,
                "url": "https://finnhub.io/api/news?id=f52c8250e0b7c5bf63adede8719b8b36ec36adf202be2253cbdc14a0b6cdcb3a",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.",
                "category": "company",
                "datetime": 1783686900,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Friday."
              },
              {
                "id": 140862541,
                "url": "https://finnhub.io/api/news?id=45fdd898ddb635e3ea7e62217e7471f63db3b33b03ca233604a1fcde9a798b28",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/10/New-York-City--New-York---September-18-2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Intel stock has more than doubled this year, but JPMorgan has named the chipmaker one of its highest-conviction short ideas for Q3.",
                "category": "company",
                "datetime": 1783677879,
                "headline": "Intel Stock Has Doubled, So Why Is JPMorgan Calling It a Top Short?"
              },
              {
                "id": 140856731,
                "url": "https://finnhub.io/api/news?id=1ab0b94ca5c3320fabd479de649c38d68888692582fd06f5482b569484475db3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to procure up to 24 million doses of the company's vaccine for Respiratory Syncytial Virus (RSV).",
                "category": "company",
                "datetime": 1783638222,
                "headline": "Why Moderna (MRNA) Stock Is Trading Up Today"
              },
              {
                "id": 140856732,
                "url": "https://finnhub.io/api/news?id=e322ebb25f950e49f4530018b3e1fb5036e82c83f93a0cfb93b68a729ff637ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has delivered a sharp 148.1% gain year to date, yet its low value score and rich market multiples suggest the stock is far from a clear bargain. Year to date, Moderna is up 148.1%, which puts recent enthusiasm firmly ahead of its longer term share price record. Excitement around Moderna's expanded mRNA pipeline beyond vaccines can support growth expectations, while concerns about ongoing losses and the time it may take to turn that pipeline into steady cash flow remain a key risk for...",
                "category": "company",
                "datetime": 1783635130,
                "headline": "Moderna (MRNA) Stock May Sit Above Fair Value Following Pipeline Expansion"
              },
              {
                "id": 140853823,
                "url": "https://finnhub.io/api/news?id=2a26c769e2fe723713c3ca7993c43989e9007a56a38e092914496d144fde5a7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.",
                "category": "company",
                "datetime": 1783617083,
                "headline": "Moderna secures up to 24 million RSV vaccine dose contract with Europe"
              },
              {
                "id": 140850090,
                "url": "https://finnhub.io/api/news?id=90c98a48106d0d071d0d6539d0652f35fc081f2126ae01931236734102528e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide ...",
                "category": "company",
                "datetime": 1783594800,
                "headline": "Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026"
              },
              {
                "id": 140850091,
                "url": "https://finnhub.io/api/news?id=0e44aa21d15e1ff44033083cb3997b69e9cd06bf4d76613889918ec489ead4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said […]",
                "category": "company",
                "datetime": 1783593674,
                "headline": "RBC Capital Raises its Price Target on Moderna (MRNA)"
              },
              {
                "id": 140850088,
                "url": "https://finnhub.io/api/news?id=e847fedf43124783edcb753cd3d81470a44d61c96f4b63d34a1e67601b823d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...",
                "category": "company",
                "datetime": 1783591935,
                "headline": "Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative?"
              },
              {
                "id": 140845441,
                "url": "https://finnhub.io/api/news?id=da22802b2eda457620ba1411857f52798b7b1503ccfea26b9b639dc0951b3b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Updates with market moves at the end of the day and latest developments.) The Dow Jones Industri",
                "category": "company",
                "datetime": 1783543202,
                "headline": "Update: Dow Logs Worst Day in 4 Weeks Amid Renewed US-Iran Tensions"
              },
              {
                "id": 140845445,
                "url": "https://finnhub.io/api/news?id=110e7076a4558bc37104c2602ca57cd4a882a6febdf966c780b80acb8657bc04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "US equity indexes closed mixed Wednesday after President Donald Trump warned of more strikes on Iran",
                "category": "company",
                "datetime": 1783542469,
                "headline": "US Equity Markets Mixed After Trump Warns of Additional Strikes on Iran"
              },
              {
                "id": 140845542,
                "url": "https://finnhub.io/api/news?id=349042fdb58e62a9028c6292e347b5b33b9c9c4da04883b7fc3172ba702dd965",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  stock has been on a long-term downtrend since the pandemic, and following a sharp run-up in June that saw shares gain nearly 50%, momentum appears to be fading.  Moderna  fell 6.4% to $74.63 on Wednesday.  Shares have slid since then, losing nearly 9% over the past two sessions.",
                "category": "company",
                "datetime": 1783540680,
                "headline": "Why Moderna Stock Is the S&P 500’s Big Loser Today"
              },
              {
                "id": 140843288,
                "url": "https://finnhub.io/api/news?id=d5ede8f585f623422b4ab059ee2e3c57d07bb05828754e457259c4d5a7652e1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Updates with latest market prices and developments.) US stocks were lower intraday after Preside",
                "category": "company",
                "datetime": 1783532386,
                "headline": "Update: Wall Street Falls Intraday as Trump Threatens to Hit Iran Again"
              },
              {
                "id": 140844537,
                "url": "https://finnhub.io/api/news?id=370518d0128fb5ab455f216fe2fdea1725e9d6bcca61fd414972dd6761174b47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The iShares USA Momentum Factor ETF is up 0.3%, while the while the Invesco Momentum ETF was moving in and out of positive territory.  Momentum ETFs like the iShares fund have actually added energy stocks, which were rising in the wake of the latest wave of re-escalation in the Iran war.  Chip stocks, many of which were actually up on the day, are also major players in momentum ETFs.",
                "category": "company",
                "datetime": 1783532165,
                "headline": "Momentum ETFs Are Actually Holding Up"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140842401,
                "url": "https://finnhub.io/api/news?id=567a839f2eac63296149dfed3ee1a72cffb17192f146fd9e30f68ba39427bd4a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1783528501,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140841131,
                "url": "https://finnhub.io/api/news?id=184ab29f606db1393fafdf742f7523325b403b70a7618e1fc5906c3e35970cdd",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wednesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1783521301,
                "headline": "Gapping S&P500 stocks in Wednesday's session"
              },
              {
                "id": 140845008,
                "url": "https://finnhub.io/api/news?id=4a277941766a5de0378493dafe626ec2f71fa68672a90db59eec27da35febbda",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783517708,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 140842639,
                "url": "https://finnhub.io/api/news?id=e3c8c78faca763456a5113d64219c755674488df3e625f6f0fc935d770bbba1a",
                "image": "https://image.cnbcfm.com/api/v1/image/108313293-1779985301248-gettyimages-2264128506-raa-broadcom260303_npRyT.jpeg?v=1783530430&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1783516753,
                "headline": "Stocks making the biggest moves midday: Broadcom, Chevron, Alibaba, Carnival & more"
              },
              {
                "id": 140851433,
                "url": "https://finnhub.io/api/news?id=f5da537e857022812576c66b6e6328b00abd252b3d1ab8c76d7ae6a44ea0d1cd",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $33 to $39.",
                "category": "company",
                "datetime": 1783516345,
                "headline": "Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $39"
              },
              {
                "id": 140839974,
                "url": "https://finnhub.io/api/news?id=ec8843d6c8224e9622ac1006028d42faed76988dfd28d5a93e7856793c594033",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1783514100,
                "headline": "Wednesday's pre-market session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 140841616,
                "url": "https://finnhub.io/api/news?id=961c0a32e8a2697dab9deacd629e37f144c77ccb61b2833357916b0c6031e247",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Oil prices spiked following an exchange of strikes between the US and Iran",
                "category": "company",
                "datetime": 1783512720,
                "headline": "Dow Jones and Nasdaq start lower as Trump says Iran ceasefire 'over'"
              },
              {
                "id": 140839747,
                "url": "https://finnhub.io/api/news?id=330deea0f937ba4fc68084a259ccf67f7595ac07a1ae24c96525a42b66911ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell ...",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Moderna Appoints Michael McDonnell to Board of Directors"
              },
              {
                "id": 140834558,
                "url": "https://finnhub.io/api/news?id=e023a6ea06713ccff1b215e8acf7fc27c2f92ddaca6d23732d3d8f3aae1d9e15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Arbutus expects to receive around $179 million from Moderna.",
                "category": "company",
                "datetime": 1783448881,
                "headline": "ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week"
              },
              {
                "id": 140831673,
                "url": "https://finnhub.io/api/news?id=c51622ca2d7ba1d3675c92f52af4f8918995e63fce8e26043dfe70b4e1372f2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny",
                "category": "company",
                "datetime": 1783436655,
                "headline": "Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says"
              },
              {
                "id": 140833660,
                "url": "https://finnhub.io/api/news?id=9290cb26cc0b705fab84a44c4bb28771dabbab0bae1ab9b4a9a8e3e64536841a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "RBC Capital  analyst Luca Issi   maintains Moderna (NASDAQ:MRNA) with a Sector Perform and raises the price target from $38 to $45.",
                "category": "company",
                "datetime": 1783425710,
                "headline": "RBC Capital Maintains Sector Perform on Moderna, Raises Price Target to $45"
              },
              {
                "id": 140833661,
                "url": "https://finnhub.io/api/news?id=fce7340a61e6e29e7cdb43cc4881dd7bafe3e7352264ecf61b28ab2da2807c6d",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "B of A Securities  analyst Dimple Gosai   maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $34 to $38.",
                "category": "company",
                "datetime": 1783419782,
                "headline": "B of A Securities Maintains Underperform on Moderna, Raises Price Target to $38"
              },
              {
                "id": 140828378,
                "url": "https://finnhub.io/api/news?id=320439d729b277339bfeaca883c1773627fd9b3d69936522b4364850bfeb8119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's growth story is just beginning.",
                "category": "company",
                "datetime": 1783416900,
                "headline": "Moderna Stock Is Soaring. Is It Too Late to Buy?"
              },
              {
                "id": 140825452,
                "url": "https://finnhub.io/api/news?id=a6086c9a0acfe0f026efc4914fc1a26adea1cdffb52524860891fb49682a58a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.",
                "category": "company",
                "datetime": 1783374605,
                "headline": "Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know"
              },
              {
                "id": 140821679,
                "url": "https://finnhub.io/api/news?id=e417f0bbb48196563d43efb3e0c4a5727402b839a8324a731be011c44b54bd6a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1783355701,
                "headline": "Stay informed with the top movers within the S&P500 index on Monday."
              },
              {
                "id": 140819547,
                "url": "https://finnhub.io/api/news?id=8f36db0f39d5c343f533b4cc188c6e182516ef6d9434d6760b4824a02baf7672",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1783341301,
                "headline": "Monday's pre-market session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 140818670,
                "url": "https://finnhub.io/api/news?id=5bb378871c4d7250110c755b530ad54ad40bcf2da5fe3ace6f349cc9076ef393",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_48_b0208efde3.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Thursday's jobs report came in far below forecasts, initially easing pressure on the Federal Reserve, before a fresh slide in memory and semiconductor stocks dragged the Nasdaq lower even as the Dow closed at a record. Tesla sold off despite its best delivery quarter in years, healthcare names caught a bid, and SK Hynix lined up what would be the largest US listing ever by a foreign company.",
                "category": "company",
                "datetime": 1783331949,
                "headline": "Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway."
              },
              {
                "id": 140818450,
                "url": "https://finnhub.io/api/news?id=8516c4a7959120da8d8950894403ed1a7173625d5052a5c7833b13be37ffa78f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Monday, Jul, 6 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 futures up about 0.4% and E-mini Nasdaq-100 futures up around 1.2%, as investors weigh cooling market anxiety against a packed data week. Volatility gauges like VIX futures are down roughly 2%, which means investors are currently pricing in a calmer trading day. At the same time, the ISM Services PMI, existing home sales, and the Federal Reserve meeting...",
                "category": "company",
                "datetime": 1783325367,
                "headline": "US Stock Market Today: S&P 500 Futures Rise As Inflation Jitters Temporarily Ease"
              },
              {
                "id": 140807809,
                "url": "https://finnhub.io/api/news?id=7210549475fc6a0d7463ca6e3d657226af06eac09f2959a9b729342bfd346624",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday’s market rotation. Cramer highlighted the stock’s significant gains during the year, as he said: If you look at the market’s best performers year to date, nearly all of them are either companies that […]",
                "category": "company",
                "datetime": 1783175414,
                "headline": "Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna”"
              },
              {
                "id": 140807702,
                "url": "https://finnhub.io/api/news?id=840cf4c4b248a268fb56ef7d1b5a446690efab5b6af1a96de06409dd422450bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock market trades largely sideways and oil dips to pre-Iran war prices heading into the final week before Q2 earnings. Here's what to watch.",
                "category": "company",
                "datetime": 1783173887,
                "headline": "Stock Market Week Ahead: Oil Hints At A Paradigm Shift"
              },
              {
                "id": 140812645,
                "url": "https://finnhub.io/api/news?id=d406aced064f84d135af82cd08c77df47c6e66da5a89e0d7894f6ab5dd22a3a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.",
                "category": "company",
                "datetime": 1783162800,
                "headline": "MarketBeat Week in Review – 06/29 - 07/03"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 2,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 104,
            "discarded_article_count": 76
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.4,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.4,
            "vcp_reason": "量縮(v10/v30=0.57)；跌縮量(近10日5日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 8120080,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 4617950,
              "avg_vol_20": 6489060,
              "avg_vol_30": 8120080,
              "range_pct_10": 0.18122947829259398,
              "range_pct_20": 0.5883801532287486,
              "range_pct_30": 0.5883801532287486,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.5687074511581167,
              "dist_to_20d_high": 0.35957943925233643,
              "down_shrink_days": 5,
              "breakout_level_20d": 85.6,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3080142613548288
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 0.9,
            "details": {
              "atrPct": 5.410616563298067,
              "turnoverUsdM": 425.331934,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 48.8878,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 10.8,
            "take_profit_price": 60.8313,
            "target_multiplier": 1.9,
            "technical_strength": 1.6,
            "take_profit_percent": 11
          },
          "positionPoints": 0.9,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 10.821233126596134,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 2.9661,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 5.41
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -70.74
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.2044
    },
    "kdj": {
      "d": 16.97,
      "j": 33.71,
      "k": 22.55,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 18.79
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 40360500,
      "recentSlope": -560330,
      "previousSlope": -3442680
    },
    "rsi": 26,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 59.3262,
      "position": "SAR喺價上",
      "distancePct": 8.22,
      "previousTrend": "下降"
    },
    "ma50": 58.4052,
    "macd": {
      "macd": -1.990316055875759,
      "trend": "看跌",
      "signal": -0.5985604501611403,
      "histogram": -1.3917556057146188
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 66.6911,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.26,
      "score": 6,
      "avgVolume": 6172610,
      "currentVolume": 7758700
    },
    "derived": {
      "ma20": 63.7438,
      "ma50": 58.4052,
      "prevClose": 57.92,
      "avgVolume10": 4938620,
      "avgVolume20": 6172610,
      "changePercent": -5.35,
      "avgVolumeForScore": 6172610
    },
    "ma_cross": {
      "ma20": 63.7438,
      "ma50": 58.4052,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 64.9908,
      "prevMa50": 58.2232,
      "spreadPct": 9.14,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 46.7056,
      "upper": 80.7819,
      "position": "中間"
    },
    "rsi_short": 41.22,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.26
    }
  }
}

{
  "close": 54.82,
  "volume": 7758700,
  "changePercent": -5.35
}